Moderate

Perioperative medication management (anticoagulants, antiplatelets, diabetes drugs, steroids; bridging)

Perioperative · Geriatric & General
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Structured management of chronic medications around surgery balances thrombotic/decompensation risk against surgical bleeding risk. Core decisions: whether and when to stop/restart anticoagulants and antiplatelets (and whether to bridge), how to manage diabetes medication and glycaemia, whether perioperative steroid cover is needed, and which other high-risk drugs (ACEi/ARB, SGLT2 inhibitors, HRT, DMARDs) to adjust. This is a DRAFT framework — always individualise to procedure bleeding risk, patient thrombotic risk and local anaesthetic/surgical protocol.

Red flags

  • Recent coronary stent (esp. <1-3 months drug-eluting) — stopping antiplatelets risks stent thrombosis; involve cardiology, defer elective surgery
  • Mechanical heart valve or VTE within 3 months — high thrombotic risk, bridging usually required
  • Emergency surgery on a DOAC/warfarin — needs reversal (idarucizumab for dabigatran, andexanet/PCC for factor Xa inhibitors, PCC + vitamin K for warfarin)
  • Patient on long-term steroids presenting unwell/hypotensive — adrenal crisis, give stress-dose hydrocortisone
  • Euglycaemic DKA in an SGLT2-inhibitor patient fasted for surgery

Assessment

Differential diagnosis

  • Decision drivers: procedure bleeding risk (low vs high), neuraxial anaesthesia planned, patient thrombotic risk (mechanical valve, recent VTE/stroke, AF CHA2DS2-VASc, recent coronary stent), renal function, urgency (elective vs emergency)

Investigations

  • Reconcile all medicines; establish indication and thrombotic risk for anticoagulant/antiplatelet
  • U&E/eGFR (DOAC stop timing is renal-dependent), FBC, coagulation; INR for warfarin (target <1.5 for most surgery)
  • HbA1c / recent glucose control; capillary glucose perioperatively +/- ketones (SGLT2i)
  • Group & save/crossmatch per procedure; assess need for steroid cover (dose & duration of exogenous steroid)

Management

  • WARFARIN: stop ~5 days before surgery; check INR day before (aim <1.5). Bridge with therapeutic LMWH ONLY if high thrombotic risk (e.g. mechanical mitral valve, VTE <3 months, recent stroke) — most AF patients do NOT need bridging (BRIDGE trial). Restart warfarin evening of surgery/next day; give prophylactic/therapeutic LMWH until INR therapeutic
  • DOACs: do NOT routinely bridge. Stop based on drug, renal function and bleeding risk — typically 24-48 h before (apixaban/rivaroxaban/edoxaban ~24 h low-risk, ~48 h high-risk; longer if eGFR low; dabigatran longer if renal impairment). Restart 24-48 h post-op once haemostasis secure; cover with prophylactic LMWH if oral delayed [verify local pathway]
  • ANTIPLATELETS: continue aspirin for most surgery (especially secondary prevention/stent). Do NOT stop dual antiplatelet therapy electively within 3 months (bare-metal/old) to 6-12 months of a coronary stent without cardiology discussion — defer elective surgery if possible; continue aspirin, stop P2Y12 inhibitor (clopidogrel ~5-7 days, ticagrelor ~3-5 days, prasugrel ~7 days) per surgical bleeding risk
  • DIABETES: for day-case/minor, manipulate usual regimen and monitor. Omit SGLT2 inhibitors >=3 days before surgery (euglycaemic DKA risk). Omit metformin on day of surgery if contrast/long fast/AKI risk. Reduce/adjust insulin (e.g. 20% reduction of long-acting the night before/day of). Use variable-rate IV insulin infusion (VRIII) for prolonged fasting/poor control/major surgery. Target glucose ~6-10 mmol/L
  • STEROIDS: patients on long-term steroids (>=5 mg prednisolone daily for weeks, or recent high-dose) need perioperative glucocorticoid cover to prevent adrenal crisis — give usual dose plus additional hydrocortisone per surgical stress
  • OTHER: consider withholding ACEi/ARB on morning of surgery (intra-op hypotension); continue beta-blockers; manage HRT/COCP VTE risk; hold methotrexate/biologics per rheumatology if infection/wound concern
  • Document a clear stop/restart plan and communicate to surgical/anaesthetic team and patient

Drugs & doses

Bridging LMWH (high thrombotic risk only): e.g. enoxaparin 1 mg/kg SC twice daily (therapeutic); last dose ~24 h pre-op; resume >=48 h post-op once haemostasis secure [verify local dose]
Prophylactic LMWH to cover delayed oral anticoagulant restart: enoxaparin 40 mg SC once daily [verify local dose]
Variable-rate IV insulin infusion (VRIII) with substrate fluid for prolonged fasting/major surgery; target glucose 6-10 mmol/L [verify local protocol]
Perioperative steroid cover: take usual oral steroid; add hydrocortisone 100 mg IV at induction then 25-50 mg IV every 6-8 h (major surgery) or hydrocortisone 25-50 mg at induction for minor, weaning over 24-72 h [verify local dose]
Omit SGLT2 inhibitors (e.g. dapagliflozin, empagliflozin) >=3 days pre-op (euglycaemic ketoacidosis); omit metformin on day of surgery if prolonged fast/contrast/AKI risk [verify local]
Vitamin K 1-2 mg IV / PO or PCC for urgent warfarin reversal before emergency surgery [verify local dose]

Disposition

Pre-assessment clinic for elective surgery with a written peri-op medication plan; inpatient for high-risk bridging/VRIII. Communicate stop/restart plan clearly to all teams and the patient.

Complications & pitfalls

  • Surgical bleeding / haematoma (inadequate stop interval) vs thrombosis (over-cautious stopping or unnecessary bridging — bridging increases bleeding)
  • Stent thrombosis / MI from premature antiplatelet cessation
  • Perioperative hypo- or hyperglycaemia, DKA (SGLT2i)
  • Adrenal crisis from inadequate steroid cover; spinal/epidural haematoma from mistimed anticoagulation

Exam pearls

  • Bridging causes more harm than good in most AF patients (BRIDGE trial) — reserve it for genuinely high thrombotic risk.
  • DOACs do not need bridging — rely on predictable pharmacokinetics; stop timing is renal-dependent (PAUSE study).
  • Stop SGLT2 inhibitors >=3 days before surgery to avoid euglycaemic DKA.
  • Never stop dual antiplatelet therapy early after a recent stent without cardiology input.
  • Guidance: NICE NG89 (perioperative VTE), BSH/ACC/ESC periprocedural anticoagulation, Joint British Diabetes Societies (JBDS) inpatient surgery guidance, Association of Anaesthetists steroid cover guidance. Verify every timing against local protocol.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.